Abbreviated Name

PCA3 Ref Set App: Zhang (2019)

Lead Investigator

Zhang, Hui L. — Johns Hopkins University School of Medicine

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Zhang, Hui L. — Johns Hopkins University School of Medicine
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

see Objectives

Aims

We propose the following two aims: 1. Determine the performance of using urinary glycoproteomics and mass spectrometry for the detection of aggressive prostate cancer. We will (a) validate 4 candidate glycoproteins to detect AG PCa in diagnostic biopsy in the NCI-EDRNs Urinary PCA3 Evaluation Trial: (b) with PCA3 trial samples further develop a glycoproteomic risk score for predicting AG Pca in diagnostic biopsy; (c) validate the utility of glycoproteins separately and in combination to predict prostate cancer with a higher tumor grade (i.e., Gleason 3+4 or greater) at radical prostatectomy with NCI-EDRN Tissue Upgrading cohort. 2. Develop and apply ELISA assays to verify the candidate glycoproteins as non-invasive urinary tests for detecting aggressive prostate cancer.

Analytic Method

No analytic method available.

Comments

No comments available.

Outcome

Samples ended up having an additive that was not compatible with the assay therefore this study will not be completed.

Secure Outcome

No secure outcome available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• ACP3
• DSC2
• PTGDS
• TMPRSS2

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Aug 1 2019

Estimated Finish Date

Mar 31 2021

Finish Date

Feb 5 2021

Protocol ID

460

Protocol Type

Reference Set

Fields of Research

• Glycomics
• Proteomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2